Vehicle Recompete: Idc 75N91019D00024
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
This is an Indefinite Delivery Contract (IDC) vehicle for the National Cancer Institute (NCI) Federally Funded Research and Development Center (FFRDC), managed by the Department of Health and Human Services. The contract operates under a massive ceiling of 10.069 billion dollars and is currently categorized as a full recompete. The ordering period for this vehicle is scheduled to end on June 25, 2026. Leidos Biomedical Research Inc is a primary contractor executing high-value task orders under this vehicle. Key initiatives include the NCI FY25 operational task order, the development of next-generation vaccines through phase 1 and 2 trials, the NIAID COVID-19 ACTIV3 project, and the Center for Serological Sciences Network. Additionally, the contract supports the management and execution of prospective observational studies regarding unknown febrile illness.
General Info
Place of Performance
Not specifiedSet-Aside
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Nci federally funded research and development center (ffrdc) contract Original Solicitation: N02CO7240681 IDV Ceiling: $10,069,000,000 Set-Aside: No set aside used. Contracting Office: NIH Nci Agencies: Department of Health and Human Services Classification: full-recompete (Confidence: high - 85/100)
Top task orders by value: - NCI FY25 OPERATIONAL TASK ORDER ($401,797,653) - LEIDOS BIOMEDICAL RESEARCH INC - THE OBJECTIVE OF THIS TASK ORDER SUPPORTS NIAIDS GOAL TO CONDUCT A SERIES OF STANDARDIZED PHASE 1 AND PHASE 2 TRIALS ON NEXT-GENERATION VACCINES TO GENERATE DATA TO INFORM DECISIONS ON WHICH CANDIDATES TO SUPPORT FOR ADVANCED DEVELOPMENT. ($292,634,066) - LEIDOS BIOMEDICAL RESEARCH INC - NIAID COVID-19 ACTIV3 ($281,604,707) - LEIDOS BIOMEDICAL RESEARCH INC - CENTER FOR SEROLOGICAL SCIENCES NETWORK (SERONET) ($143,577,599) - LEIDOS BIOMEDICAL RESEARCH INC - DCR IS REQUESTING THE SERVICES OF LEIDOS BIOMEDICAL RESEARCH, INC. TO INITIATE MANAGEMENT, OVERSIGHT, EXECUTION, CLOSEOUT AND PUBLICATION OF FINDINGS OF A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT AND PEDIATRIC PATIENTS WITH UNKNOWN FEBRILE ILLNESS FR ($89,188,376) - LEIDOS BIOMEDICAL RESEARCH INC
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → NIH Nci
Same awarding agency
Earlier notices in this NAICS code
Posted before this notice, open and closed
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
